William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty

Group 1 - uniQure N.V. (NASDAQ:QURE) is considered one of the most oversold biotech stocks, with a reaffirmed Market Perform rating from William Blair [1] - The company is facing regulatory challenges regarding its AMT-130 therapy, as the FDA no longer deems the results from Phase 1/2 studies sufficient for a Biologics License Application (BLA) [2] - uniQure anticipates receiving final minutes from the pre-BLA meeting within 30 days and plans to engage proactively with the FDA for accelerated approval of AMT-130 [3] Group 2 - The strong clinical results released last month and early interest from patients and physicians for the Huntington's disease medication may lead to pressure on regulators for a quicker BLA submission [1]